Cencora Inc., US03073E1055

Cencora stock: FTC sues to block MWI sale

Published on 11/16/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora stock faces a federal antitrust challenge to its planned MWI Animal Health sale. The case puts the transaction on a court timetable.

Antitrust case changes deal outlook

  • The FTC says the proposed transaction would combine the two largest US veterinary distributors.
  • A federal court in New York will consider the agency's request for a permanent injunction.
  • Cencora's MWI sale now faces a regulatory dispute that could affect the planned transaction timeline.
Cencora Inc., US03073E1055, Illustration mit AI erstellt.

Cencora's planned sale of MWI Animal Health to Covetrus faces a federal antitrust challenge. The Federal Trade Commission said on November 13, 2026, that it sued to block the transaction, which values MWI at 3.5 billion US dollars.

The agency alleges that Covetrus and MWI are the two largest suppliers in US veterinary clinic distribution and distribution to large corporate accounts. In its complaint, the FTC argues that combining the businesses could raise costs for veterinary clinics, reduce service quality and increase prices for pet owners.

The FTC said the complaint was filed in the US District Court for the Southern District of New York. The Commission voted 2-0 to authorize staff to seek a permanent injunction, and attorneys general from 13 states joined the complaint. The agency also said the companies compete in pharmaceuticals, vaccines, surgical supplies and other veterinary products and services.

Deal timing moves into court

The lawsuit changes the status of a transaction that Cencora had planned to complete through the sale of its animal-health business. The court process creates a new execution risk for investors because regulatory approval is now central to the deal's timetable.

The FTC said Covetrus and MWI have competed through pricing, rebates and national distribution networks. It also described Vetcove, an online price-comparison platform, as a factor that has intensified competition between the two distributors. These allegations are set out in the agency's FTC release.

Investor focus shifts to execution

Cencora stock traded at 325.95 euros on Lang & Schwarz at 16:02 CET on Monday, November 16, 2026.

The antitrust case adds a regulatory variable to Cencora's broader fiscal 2027 plan. Investors will now focus on the court timetable, the parties' responses and whether the proposed sale can proceed on its planned terms.

US healthcare shares trade against the broader market backdrop shown in Current market reports.

More news and analyses are available on Cencora stock.

Cencora company facts

  • Company: Cencora, Inc.
  • ISIN: US03073E1055
  • Ticker: COR
  • Home exchange: NYSE
  • Lang & Schwarz quote: 325.95 euros at 16:02 CET on November 16, 2026
Disclaimer...
en | US03073E1055 | CENCORA INC. | boerse | 70521433 | bgmi